3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase EARLY_PHASE1
1
Phase 1/2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
79
Cyclophosphamide
55
Specimen Handling
54
Carboplatin
50
fludarabine
44
Nivolumab
42
Magnetic Resonance Spectroscopy
42
Biopsy
38
Gemcitabine
37
Bevacizumab
34
Dexamethasone
31
venetoclax
27
Paclitaxel
26
Injections
25
Docetaxel
25
atezolizumab
24
Pemetrexed
24
Cisplatin
24
Ipilimumab
23
Capecitabine
21
Temozolomide
19
Fulvestrant
19
abemaciclib
18
Rituximab
18
Oxaliplatin
18
Lenalidomide
18
Cetuximab
18
Azacitidine
18
Vincristine
15
Fluorouracil
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Cell- and Tissue-Based Therapy
×
90 days
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled